CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • CD22 (CD22 Molecule) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL4 (Interleukin 4)

CD19 expression

11ms

A Study of CAR2219 CAR-T cell in subjects with relapsed/refractory CD19/CD22 positive B cell Lymphoma (ChiCTR2400094375)

P1, N=20, The First Medical Center of PLA General Hospital, China; the First Medical Center of PLA General Hospital

11 months ago

New P1 trial

CD19 (CD19 Molecule) • CD22 (CD22 Molecule)

CD19 expression

11ms

Phase I study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult B-ALL patients. (PubMed, Blood Adv)

In contrast, the DOR was limited in those with high marrow burden, highlighting a remaining critical need to identify new strategies to prolong remissions. We observed similar outcomes in CAR-naïve adult B-ALL patients receiving CD19 CAR T-cells expressing a fully human or murine scFv-containing CAR.

11 months ago

P1 data • Journal

CD8 (cluster of differentiation 8)

CD19 expression

11ms

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov)

P1, N=44, Completed, National Cancer Institute (NCI) | Recruiting --> Completed | N=150 --> 44 | Trial completion date: Dec 2040 --> Jan 2025 | Trial primary completion date: Dec 2025 --> Jul 2024

11 months ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date

CD19 (CD19 Molecule) • CD22 (CD22 Molecule)

CD19 expression • CD22 expression

cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells

11ms

ALLG NHL41: A phase I clinical trial investigating the combination of chimeric antigen receptor-T cell (CAR-T) cell therapy with Zanubrutinib bridging and subsequent Zanubrutinib and Tislelizumab consolidation in patients with relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL). (ACTRN12625000001493)

P1, N=25, Not yet recruiting, Australasian Leukaemia and Lymphoma Group (ALLG)

11 months ago

New P1 trial

CD19 (CD19 Molecule)

CD19 positive • CD19 expression

Tevimbra (tislelizumab-jsgr) • cyclophosphamide • Brukinsa (zanubrutinib) • fludarabine IV

11ms

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (clinicaltrials.gov)

P1, N=64, Recruiting, Baylor College of Medicine | Trial primary completion date: Dec 2024 --> Dec 2025

11 months ago

Trial primary completion date

CD19 (CD19 Molecule)

CD19 positive • CD19 expression

11ms

Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (clinicaltrials.gov)

P1, N=48, Enrolling by invitation, Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting --> Enrolling by invitation | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Dec 2025

11 months ago

Enrollment status • Trial completion date • Trial primary completion date

CD19 (CD19 Molecule)

CD19 expression • CD20 negative

CB CAR-NK019

11ms

CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL (clinicaltrials.gov)

P1/2, N=35, Recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

11 months ago

Trial completion date • Trial primary completion date

CD19 (CD19 Molecule) • CD22 (CD22 Molecule)

CD19 expression

CD22/CD19 CAR T

11ms

MED20-165: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)

P1, N=6, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026

11 months ago

Trial completion date • Trial primary completion date

CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)

CD19 expression

apamistamab-I-131 (Iomab-ACT)

12ms

Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen. (PubMed, J Immunother Cancer)

Based on specificity, efficacy, and loss of the target antigen, CARLY3 represents a potential novel CAR treatment for NHL.

12 months ago

Preclinical • Journal • IO biomarker

CD20 (Membrane Spanning 4-Domains A1) • CD79B (CD79b Molecule) • CD22 (CD22 Molecule)

CD19 expression • CD79B expression

Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Qartemi (varnimcabtagene autoleucel) • cesnicabtagene autoleucel (ARI0002h)

12ms

RUNX1::CBFA2T2 rearranged acute myeloid leukemia transformed from JAK2 V617F mutated primary myelofibrosis. (PubMed, EJHaem)

The immunophenotype and the landscape of cooperative gene alterations in AML with RUNX1::CBFA2T2 resemble those of AML with RUNX1::RUNX1T1, including expression of CD19, cooperative gene alterations in signaling pathway (JAK2), epigenetic/chromatin and cell cycle regulation (TET2, SMC3, and CDKN2A/B), and additional chromosomal abnormalities (trisomies 8 and 15). This case study provides insights into the pathogenesis of this rare subtype of AML.

12 months ago

Journal

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • JAK2 (Janus kinase 2) • CD19 (CD19 Molecule) • RUNX1 (RUNX Family Transcription Factor 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)

CD19 expression • JAK2 V617F • JAK2 mutation